IFNB1 and myeloid sarcoma: Concerning the current coronavirus pandemic, recent functional in vitro analysis found that IFN-β treatment effectively blocks SARS-CoV-2 replication in a dose-dependent manner, indicating a possible side benefit for MS patients treated with IFN-β [46].